HL Deb 25 November 1996 vol 576 c4WA
The Countess of Mar

asked Her Majesty's Government:

What steps they have taken to ensure that Malathion used for treatment of ectoparasites in humans is free from impurities such as OOS-TMP and OSS-TMP, and whether the shelf life and storage conditions of these products are controlled.

The Parliamentary Under-Secretary of State, Department of Health (Baroness Cumberlege)

Before any medicinal product is granted a marketing authorisation by the Medicines Control Agency (MCA) the applicant must satisfy the MCA that the product is safe, efficacious and of good quality. In doing this, the applicant will need to address issues such as impurities and justify appropriate storage conditions and shelf life for the product.